07 May 2021>: Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta 123ABCDEF , Vanina Bongard 12ABCDEF , Frédéric Bouisset 12ABCDEF , Dorota Taraszkiewicz 12ABCDEF , Jean-Pierre Rabès 4BDEF , Jean Ferrières 12ABCDEFG*DOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784
Figure 2 Waterfall plot of the variation (%) in low-density lipoprotein cholesterol of 123 heterozygous familial hypercholesterolemia patients after initiation of PCSK9i. PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitor.